Publications
58
Citations
251
Est. group size
~1
Recurring co-author estimate
Active years
15
Publishing since 2011
This researcher focuses on blood cancers, particularly leukemias (chronic lymphocytic leukemia, acute myeloid leukemia) and myelodysplastic syndromes, studying treatment outcomes, drug response, and molecular/genetic markers that predict how patients respond to therapy. Some work also touches on kidney complications related to blood disorders, such as cast nephropathy and glomerulonephritis linked to abnormal antibody proteins. The research is largely clinical, drawing on patient data to evaluate treatments like pirtobrutinib, venetoclax, and rituximab.
Publication output grew markedly after 2020, peaking sharply in 2024, following several years with no recorded output before 2020.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
Blood Cancer Journal · 2025
- Do we still need plasma exchange to treat TMA? Yes
Nephrology Dialysis Transplantation · 2025
- Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
Research Square · 2025
- Heavy Chain Cast Nephropathy in a Gamma Heavy Chain Disease: RESPONSE to High-Dose Therapy Melphalan and Daratumumab
Clinical Lymphoma Myeloma & Leukemia · 2025
- Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis
JCO Oncology Practice · 2024
- Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Clinical Cancer Research · 2024
- Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib
Blood Advances · 2024
- Acute myocardial infarction in an untreated patient with acute myeloid leukemia
Clinical Case Reports · 2024
- Rituximab for Patients with Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID): A Case Series
Journal of the American Society of Nephrology · 2024
- Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024
- Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024
- Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024
- Data from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024
- Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024
- Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024
- Blood×10
- Journal of Investigative Medicine High Impact Case Reports×5
- HemaSphere×3
- Blood Cancer Journal×2
- Journal of the American Society of Nephrology×2
- Brian Giacopelli
Medicine · The Ohio State University
- Yosra Ben Youssef
Medicine · The Ohio State University
- Jae Yoon Jeon
Medicine · The Ohio State University
- C. D. Bloomfield
Medicine · The Ohio State University
- Terri Guinipero
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile